US: 1.646.568.9797 (24x5)
UK: 44.330.808.0580 (24x5)
Worldwide: 91.703.051.960 (24x7)
Abstract, Snapshot, Market Analysis & Market Definition: Global Heparin MarketThe global Heparin market size is projected to reach US$ 7.37 billion by 2026, from US$ 6.7 billion in 2020, at a CAGR of 1.6% during 2021-2026. Increasing number of accidents and surgeries is expected to be a key driver for the growth. Increasing incidence of venous thromboembolism and cardiovascular disorders is expected to fuel the market growth over the forecast period. According to the data published in the Centers for Disease Control and Prevention (CDC) in 2018, around 900,000 people in U.S. are affected by deep vein thrombosis and pulmonary embolism each year. This factor is projected to propel the regional demand in the forthcoming years. Some biopharmaceutical companies are financing resources for the development of new drugs. Organizations such as the CDC and the National Institutes of Health (NIH) are undertaking initiatives for increasing awareness levels through programs that aim preventing thrombosis-associated complications in initial stages. High demand for anticoagulants is anticipated to boost the overall heparin market. Furthermore, high healthcare expenditures and patient awareness levels are some of the key factors anticipated to accelerate the market over the forecast period.
Market Segmentation, Outlook & Viewpoint: Global Heparin Market
Type Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2026)
- Low Molecular Weight Heparin
- Ultra-low Molecular Weight Heparin
- Unfractionated Heparin
Route of Administration Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2026)
Application Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2026)
- Venous Thromboembolism
- Atrial Fibrillation
- Renal Impairment
- Coronary Artery Disease
End Use Market Segmentation & Outlook (Revenue, USD Million, 2014 - 2026)
Key Players, Recent Developments & Regional Insights: Global Heparin MarketBased on the application, the market has been categorized into venous thromboembolism, atrial fibrillation, renal impairment, and coronary artery disease. Among these, coronary artery disease held the largest share in 2018 owing to increasing prevalence and incidence of heart-related disorders. According to statistics published in the American Heart Association, in 2018, around 92.1 million American adults were suffering from some form of cardiovascular disease. In addition, around 1 in every 3 deaths are caused by cardiovascular disease in the U.S. accounting for around 2,300 deaths per day. Venous thromboembolism (VTE) is expected to be the fastest growing segment over the forecast period. Venous thromboembolism is segmented into pulmonary embolism (PE) and deep vein thrombosis (DVT). Increasing awareness of thrombosis is one of the major factors driving the segment growth. For instance, introduction of online portal by International Society on Thrombosis and Haemostasis, Inc. is expected to improve the awareness of thrombosis amongst patients. Moreover, increasing mortality rates of venous thromboembolism is anticipated to contribute towards the segment growth. According to the facts published in the International Society on Thrombosis and Haemostasis, Inc., around 10 million cases of VTE is recorded globally every year and around 544,000 VTE related deaths are observed every year in Europe.
End Use InsightsOn the basis of end use, the market is segmented into inpatients and outpatients. Outpatient was the largest segment in 2018 and is estimated to witness the fastest CAGR of 2.4% over the forecast period. Increasing preference of subcutaneous route of administration among the patients is a major factor responsible for market growth. In addition, outpatient hospital cost is less as compared inpatient hospital cost. Moreover, according to various studies published in the NCBI, outpatient therapy was associated with lower rate of recurrent venous thromboembolism.
Regional InsightsIn 2018, North America led the overall market in terms of revenue owing to the increasing sports injury and cardiovascular disorders. Furthermore, higher healthcare expenditure levels, high patient awareness, and sophisticated healthcare infrastructure in this region are the factors that can be attributed to the regions high share. According to the American Physical Therapy Association, the average annual injury is around 8.6 million every year accounting for an age-adjusted rate of 34.1 per 1000 population. It was also stated that around 65% of the injuries were caused among individuals aged 5-24 years. Asia Pacific is anticipated to witness the fastest growth in the forthcoming years. Constantly improving healthcare infrastructure, presence of untapped opportunities, economic development, and rising initiatives by private and public organizations are some factors that can be accredited to the rapid growth of the region.
Heparin Market Share InsightsThe key players are GlaxoSmithKline plc; Pfizer, Inc.; Baxter; Leo Pharma A/S; Sanofi; Dr. Reddys Laboratories Ltd.; Aspen Holdings; B. Braun Medical Inc.; Fresenius SE & Co. KGaA; and Teva Pharmaceutical Industries Ltd. Mostly, the companies are involved in implementing strategies such as mergers and acquisitions, collaborations, and product development to increase their market share. For instance, in 2018, Fresenius Kabi launched heparin sodium in ready-to-administer non DEHP freeflex bags, thus expanding the companys critical care portfolio.
Key Insights Covered: Global Heparin Market1. North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Heparin industry. 2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Heparin industry. 3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Heparin industry. 4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Heparin industry. 5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of Heparin industry.
Research Methodology: Global Heparin Market
- Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
- Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
- Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among other
Table of Contents Chapter 1. Methodology and Scope 1.1. Market Segmentation & Scope 1.2. Market Definition 1.3. Information Procurement 1.3.1. Purchased Database 1.3.2. HCC’s Internal Database 1.3.3. Secondary sources & third-party perspectives 1.3.4. Primary research 1.4. Information Analysis 1.4.1. Data Analysis Models 1.5. Market Formulation & Data Visualization 1.6. Data Validation & PublishingChapter 2. Executive Summary 2.1. Market Outlook 2.2. Segment Outlook 2.3. Competitive InsightsChapter 3. Global Heparin Market Variables, Trends & Scope 3.1. Hep | read more...